drugset / Trial / NCT01532544
Integrilin and Ilomedin in Combination in Comparison to Standard Treatment in Severe Pneumonia Patients With Severe Sepsis
Phase 2
Terminated
5 enrolled
Thrombologic ApS
Anders Perner · collabRigshospitalet, Denmark · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is an investigator sponsored double-blinded, multinational, multi center, randomized (2:1 active:placebo), placebo-controlled, phase IIa trial in severe pneumonia patients with severe sepsis or septic shock, investigating the safety and efficacy of co-administration of Iloprost and escalating doses of Eptifibatide for continuous intravenous infusion in totally 36 patients.
Timeline
- Start
- 2012-06
- Primary completion
- 2014-03
- Completion
- 2014-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eptifibatide | Other / unclassified | — | Intravenous |
| Subject | Iloprost | Other / unclassified | — | Intravenous |